Figure 2
From: A novel immune prognostic index for stratification of high-risk patients with early breast cancer
Kaplan–Meier plots of disease-free survival (DFS) or distant metastasis-free survival (DMFS) in the clinical and proliferation high-risk (CPH) group within the discovery dataset. (a) Total population and (b) subgroup analysis according to the molecular subtype (HR+/HER2−, HR+/HER2+, HR−/HER2+ breast cancer and TNBC). Patients were classified into three risk groups according to the immune prognostic index. Optimal cutoff points for the immune prognostic index used for risk classification were determined using maximally selected rank statistics.
